BibTex RIS Cite

-

Year 2013, Volume 35, Issue 4 (2013): Supplement, 42 - 49, 14.02.2014

Hakan Taşolar , Hasan Pekdemir

Abstract

Degeneration and occlusion of saphenous vein grafts (SVG) has been a serious problem in patients who underwent coronary artery bypass surgery. Although a variety of treatment methods have been developed for the SVG occlusion, the most suitable option is not yet known. Because re-do surgical intervention has high morbidity and mortality, most of the center prefer to percutaneous coronary intervention in this group of patients. Past to present many studies and meta-analysis were made compared with balloon angioplasty, covered stents, bare metal stents and drug-eluting stents in SVG lesions. Large-scale, randomized, controlled clinical studies are needed to demonstrate the efficiency and safety of the use of drug eluting stents which appear to be comparatively the most effective method.

Keywords

Saphenous vein percutaneous balloon angioplasty stent drug-eluting stent

References

  • Motwani MD, Topol EJ. Aortocoronary saphenous vein graft disease. Circulation 1998; 97: 916-31.
  • Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-32.
  • Halabi AR, Alexander JH, Shaw LK, Lorenz TJ, Liao L, Kong DF, Milano CA, Harrington RA, Smith PK. Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol 2005; 96: 1254Weintraub WS, Jones EL, Craver JM, Guyten RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 1994; 73: 103-12.
  • Cameron A, Kemp HG Jr, Green GE. Reoperation for coronary artery disease: 10 years of clinical follow-up. Circulation 1988; 78: 158-62.
  • Coolong A, Baim DS, Kuntz RE, O’Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008; 117: 790-7.
  • Hindnavis V, Cho SH, Goldberg S. Saphenous vein graft intervention: A review. J Invasive Cardiol 2012; 24: 64-71.
  • Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, Stone GW. Saphenous vein graft intervention. JACC Cardiovasc Interv 2011; 4: 831-43.
  • Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337: 740Hanekamp CE, Koolen JJ, Den Heijer P, Schalij MJ, Piek JJ, Bär FW, De Scheerder I, Bonnier HJ, Pijls NH. Venestent Study Group. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: The Venestent study. Catheter Cardiovasc Interv 2003; 60: 452-7.
  • Mattos LA, Sousa AG, Campos Neto CM, Labrunie A, Alves CR, Feres F, Soares Neto MM, Saad J. The use of primary stenting or balloon percutaneous transluminal coronary angioplasty for the treatment of acutely occluded saphenous vein grafts. Results from the Brazilian National Registry-CENIC. Arq Bras Cardiol 2001; 76: 483-95.
  • Schächinger V, Hamm CW, Münzel T, Haude M, Baldus S, Grube E, Bonzel T, Konorza T, Köster R, Arnold R, Haase J, Probst P, vom Dahl J, Neumann FJ, Mudra H, Hennen B, Thiele L, Zeiher AM. STENTS (STents IN Grafts) Investigators. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003; 42: 1360-9.
  • Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME. Pivotal, randomized U.S. study of the Symbiot trade mark covered stent system in patients with saphenous vein graft disease: Eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 2006; 68: 379-88.
  • Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, Niccoli L, Bartorelli AL, Rubartelli P, Reifart N, Heyndrickx GR, Saunamäki K, Morice MC, Sgura FA, Di Mario C. Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts investigators. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003; 108: 37-42. Stone GW, Goldberg S, O’Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-year follow-up of polytetrafluoroethylenecovered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: Restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv 2011; 4: 300-9.
  • Abizaid A, Weiner B, Bailey SR, Londero H. Use of a self-expanding superelastic all-metal endoprosthesis; to treat degenerated SVG lesions: The SESAME first in man trial. Catheter Cardiovasc Interv 2010; 76: 781-6.
  • Colombo A, Almagor Y, Gaspar J, Vonderwalde C. The pericardium covered stent (PCS).EuroIntervention 2009; 5: 394-9.
  • Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005; 45: 989-94.
  • Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drugeluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005; 66: 507-11.
  • Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-7.
  • Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48: 2423-31.
  • Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. DELAYED RRISC (Death and Events at Longterm follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50: 261-7.
  • Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.J Am Coll Cardiol 2009; 53: 919-28.
  • Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011; 4: 176-82.
  • Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A. Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet 2011; 378: 1071-8.
  • Chakravarty T, Morrissey RP, Wertman B, Naghi J, Chou S, Goykhman P, Doctor N, Mirocha J, Forrester JS, Makkar R. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis. Catheter Cardiovasc Interv 2012; 79: 903-9.
  • Nauta ST, Van Mieghem NM, Magro M, Deckers JW, Simsek C, Van Geuns RJ, Van Der Giessen WJ, De Jaegere P, Regar E, Van Domburg RT, Serruys PW. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts. Catheter Cardiovasc Interv 2012; 79: 912-8.
  • Lupi A, Navarese EP, Lazzero M, Sansa M, De Servi S, Serra A, Bongo AS, Buffon A. Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients. Circ J 2011; 75: 280-9.
  • Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: A systematic review and meta-analysis. JACC Cardiovasc Interv 2010; 3: 1262-73.
  • Fröbert O, Scherstén F, James SK, Carlsson J, Lagerqvist B. Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts. Am Heart J 2012; 164: 87-93.
  • Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA. STENT Group. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2009; 2: 1105-12.
  • Chu WW, Kuchulakanti PK, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006; 19: 121-5.
  • Görmez S, Erdim R, Erdoğmuş O, Civan M, Catakoğlu AB, Gülbaran M, Demiroğlu C, Aytekin V. Treatment of saphenous vein graft lesions with paclitaxel- and sirolimus-eluting stents: Comparison of short-and long-term clinical outcomes. Anadolu Kardiyol Derg 2008; 8: 431-6.
  • Lee MS, Hu PP, Aragon J, Shah AP, Oyama J, Dhoot J, Iqbal Z, Jones N, Penny W, Tobis J, Mahmud E, French W. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry). Am J Cardiol 2010; 106: 337-41.
  • Papayannis AC, Michael TT, Yangirova D, Abdel-Karim AR, Kohlhaas J, Mahmood A, Addo T, Haagen D, Makke L, Roesle M, Rangan B, Banerjee S, Brilakis ES. Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) Xience V Study: Use of the everolimus-eluting stent in saphenous vein graft lesions. J Invasive Cardiol 2012; 24: 390-4.
  • Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, Leon MB, Moses JW, Yock PG, Honda Y, Kuntz RE, Fitzgerald PJ. SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-63.
  • Hsieh IC, Chien CC, Chang HJ, Chern MS, Hung KC, Lin FC, Wu D. Acute and long-term outcomes of stenting in coronary vessel >3.0 mm, 3.0-2.5 mm, and Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875-80.
  • Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, Aymong E. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol 2004; 93: 963-8.
  • Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, Ahn Y, Jeong MH, Satler LF, Kent KM, Suddath WO, Weissman NJ, Kang JC, Waksman R. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol 2010; 105: 179-85.

Safen ven greft tıkanıklıklarında balon anjiyoplasti ve stent uygulamalarına güncel bakış

Year 2013, Volume 35, Issue 4 (2013): Supplement, 42 - 49, 14.02.2014

Hakan Taşolar , Hasan Pekdemir

Abstract

Özet

Safen ven greftlerin (SVG) dejenerasyonu ve tıkanıklığı koroner baypas cerrahisi uygulanan hastalarda ciddi bir sorun teşkil etmektedir. SVG tıkanıklığı için çeşitli tedavi yöntemleri geliştirilmiş olmasına rağmen henüz en uygun seçenek bilinmemektedir. Bu hasta grubunda tekrar cerrahi girişim yüksek morbidite ve mortaliteye sahip olduğundan çoğu merkez perkütan koroner girişime yönelmektedir. Geçmişten günümüze SVG lezyonlarında balon anjiyoplasti, kaplı stentler, çıplak metal stentler ve ilaç kaplı stentleri karşılaştıran birçok çalışma ve metaanaliz yapılmıştır. Nispeten en etkili yöntem gibi görünen ilaç kaplı stent kullanımının etkinlik ve güvenirliliğini göstermek için geniş çaplı, randomize, kontrollü klinik çalışmalara ihtiyaç vardır.

Anahtar sözcükler: Safen ven, koroner balon anjiyoplasti, stent, ilaç salınımlı stent

Keywords

Safen ven koroner balon anjiyoplasti stent ilaç salınımlı stent

References

  • Motwani MD, Topol EJ. Aortocoronary saphenous vein graft disease. Circulation 1998; 97: 916-31.
  • Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-32.
  • Halabi AR, Alexander JH, Shaw LK, Lorenz TJ, Liao L, Kong DF, Milano CA, Harrington RA, Smith PK. Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol 2005; 96: 1254Weintraub WS, Jones EL, Craver JM, Guyten RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 1994; 73: 103-12.
  • Cameron A, Kemp HG Jr, Green GE. Reoperation for coronary artery disease: 10 years of clinical follow-up. Circulation 1988; 78: 158-62.
  • Coolong A, Baim DS, Kuntz RE, O’Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008; 117: 790-7.
  • Hindnavis V, Cho SH, Goldberg S. Saphenous vein graft intervention: A review. J Invasive Cardiol 2012; 24: 64-71.
  • Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, Stone GW. Saphenous vein graft intervention. JACC Cardiovasc Interv 2011; 4: 831-43.
  • Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337: 740Hanekamp CE, Koolen JJ, Den Heijer P, Schalij MJ, Piek JJ, Bär FW, De Scheerder I, Bonnier HJ, Pijls NH. Venestent Study Group. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: The Venestent study. Catheter Cardiovasc Interv 2003; 60: 452-7.
  • Mattos LA, Sousa AG, Campos Neto CM, Labrunie A, Alves CR, Feres F, Soares Neto MM, Saad J. The use of primary stenting or balloon percutaneous transluminal coronary angioplasty for the treatment of acutely occluded saphenous vein grafts. Results from the Brazilian National Registry-CENIC. Arq Bras Cardiol 2001; 76: 483-95.
  • Schächinger V, Hamm CW, Münzel T, Haude M, Baldus S, Grube E, Bonzel T, Konorza T, Köster R, Arnold R, Haase J, Probst P, vom Dahl J, Neumann FJ, Mudra H, Hennen B, Thiele L, Zeiher AM. STENTS (STents IN Grafts) Investigators. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003; 42: 1360-9.
  • Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME. Pivotal, randomized U.S. study of the Symbiot trade mark covered stent system in patients with saphenous vein graft disease: Eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 2006; 68: 379-88.
  • Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, Niccoli L, Bartorelli AL, Rubartelli P, Reifart N, Heyndrickx GR, Saunamäki K, Morice MC, Sgura FA, Di Mario C. Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts investigators. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003; 108: 37-42. Stone GW, Goldberg S, O’Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-year follow-up of polytetrafluoroethylenecovered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: Restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv 2011; 4: 300-9.
  • Abizaid A, Weiner B, Bailey SR, Londero H. Use of a self-expanding superelastic all-metal endoprosthesis; to treat degenerated SVG lesions: The SESAME first in man trial. Catheter Cardiovasc Interv 2010; 76: 781-6.
  • Colombo A, Almagor Y, Gaspar J, Vonderwalde C. The pericardium covered stent (PCS).EuroIntervention 2009; 5: 394-9.
  • Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005; 45: 989-94.
  • Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drugeluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005; 66: 507-11.
  • Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-7.
  • Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48: 2423-31.
  • Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. DELAYED RRISC (Death and Events at Longterm follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50: 261-7.
  • Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.J Am Coll Cardiol 2009; 53: 919-28.
  • Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011; 4: 176-82.
  • Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A. Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet 2011; 378: 1071-8.
  • Chakravarty T, Morrissey RP, Wertman B, Naghi J, Chou S, Goykhman P, Doctor N, Mirocha J, Forrester JS, Makkar R. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis. Catheter Cardiovasc Interv 2012; 79: 903-9.
  • Nauta ST, Van Mieghem NM, Magro M, Deckers JW, Simsek C, Van Geuns RJ, Van Der Giessen WJ, De Jaegere P, Regar E, Van Domburg RT, Serruys PW. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts. Catheter Cardiovasc Interv 2012; 79: 912-8.
  • Lupi A, Navarese EP, Lazzero M, Sansa M, De Servi S, Serra A, Bongo AS, Buffon A. Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients. Circ J 2011; 75: 280-9.
  • Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: A systematic review and meta-analysis. JACC Cardiovasc Interv 2010; 3: 1262-73.
  • Fröbert O, Scherstén F, James SK, Carlsson J, Lagerqvist B. Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts. Am Heart J 2012; 164: 87-93.
  • Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA. STENT Group. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2009; 2: 1105-12.
  • Chu WW, Kuchulakanti PK, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006; 19: 121-5.
  • Görmez S, Erdim R, Erdoğmuş O, Civan M, Catakoğlu AB, Gülbaran M, Demiroğlu C, Aytekin V. Treatment of saphenous vein graft lesions with paclitaxel- and sirolimus-eluting stents: Comparison of short-and long-term clinical outcomes. Anadolu Kardiyol Derg 2008; 8: 431-6.
  • Lee MS, Hu PP, Aragon J, Shah AP, Oyama J, Dhoot J, Iqbal Z, Jones N, Penny W, Tobis J, Mahmud E, French W. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry). Am J Cardiol 2010; 106: 337-41.
  • Papayannis AC, Michael TT, Yangirova D, Abdel-Karim AR, Kohlhaas J, Mahmood A, Addo T, Haagen D, Makke L, Roesle M, Rangan B, Banerjee S, Brilakis ES. Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) Xience V Study: Use of the everolimus-eluting stent in saphenous vein graft lesions. J Invasive Cardiol 2012; 24: 390-4.
  • Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, Leon MB, Moses JW, Yock PG, Honda Y, Kuntz RE, Fitzgerald PJ. SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-63.
  • Hsieh IC, Chien CC, Chang HJ, Chern MS, Hung KC, Lin FC, Wu D. Acute and long-term outcomes of stenting in coronary vessel >3.0 mm, 3.0-2.5 mm, and Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875-80.
  • Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, Aymong E. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol 2004; 93: 963-8.
  • Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, Ahn Y, Jeong MH, Satler LF, Kent KM, Suddath WO, Weissman NJ, Kang JC, Waksman R. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol 2010; 105: 179-85.
There are 36 citations in total.

Details

Primary Language Turkish
Journal Section Reviews
Authors

Hakan Taşolar

Hasan Pekdemir

Publication Date February 14, 2014
Published in Issue Year 2013Volume 35, Issue 4 (2013): Supplement

Cite

AMA Taşolar H, Pekdemir H. Safen ven greft tıkanıklıklarında balon anjiyoplasti ve stent uygulamalarına güncel bakış. CMJ. February 2014;35(4):42-49.